Highlights vom ERA 2025 in Wien
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
Highlights vom ERA 2025 in Wien
-
Narrado por:
-
De:
Dr. Marcus Säemann präsentiert seine Highlights vom ERA 2025 in Wien.
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
https://www.nejm.org/doi/abs/10.1056/NEJMoa2410659
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
https://www.nejm.org/doi/full/10.1056/NEJMoa2501006
ARO-C3, an investigational RNAi Therapeutic Targeting Complement C3, Reduces Proteinuria, Hematuria, andComplement Activity in IgAN Patients
https://ir.arrowheadpharma.com/static-files/71ace783-f6cd-47ac-b9a5-5809c13b70f1
Pegcetacoplan for C3G and primary (idiopathic) IC-MPGN: 52-week results from the phase 3 VALIANT trial show sustained efficacy
https://sciencelibrary.sobi.com/sites/default/files/documents/Fakhouri_VALIANT_52w_ERA2025_Oral.pdf
Impact of acute eGFR dips and markers of disease severity on effects of empagliflozin on acute kidney outcome
https://era-apps.m-anage.com/era25/en-GB/pag/presentation/505078#xd_co_f=NGQ1M2RkMjgtOTdjOC00NjgwLTk4NjQtZjJmZTUxYmJkNTcw~
https://www.youtube.com/watch?v=bX2Xtj_8mkg
https://www.renalandurologynews.com/reports/egfr-dip-empagliflozin-initiation-acute-renal-risks-treatment/#:~:text=Dr%20Staplin's%20team%20concluded%2C%20%E2%80%9CEmpagliflozin,of%20these%20diseases'%20severity.%E2%80%9D
Dieser Podcast wurde mit freundlicher Unterstützung von Boehringer Ingelheim RCV GmbH & Co realisiert.
Support the show